Last reviewed · How we verify
GnRH antagonist depot Degarelix
GnRH antagonist depot Degarelix is a Small molecule drug developed by Bioroma. It is currently in Phase 2 development.
At a glance
| Generic name | GnRH antagonist depot Degarelix |
|---|---|
| Sponsor | Bioroma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (PHASE1)
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- The COSMYC Trial (COmbined Suppression of MYC) (PHASE2)
- Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)
- A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (PHASE2)
- A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PHASE3)
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRH antagonist depot Degarelix CI brief — competitive landscape report
- GnRH antagonist depot Degarelix updates RSS · CI watch RSS
- Bioroma portfolio CI
Frequently asked questions about GnRH antagonist depot Degarelix
What is GnRH antagonist depot Degarelix?
GnRH antagonist depot Degarelix is a Small molecule drug developed by Bioroma.
Who makes GnRH antagonist depot Degarelix?
GnRH antagonist depot Degarelix is developed by Bioroma (see full Bioroma pipeline at /company/bioroma).
What development phase is GnRH antagonist depot Degarelix in?
GnRH antagonist depot Degarelix is in Phase 2.
Related
- Manufacturer: Bioroma — full pipeline
- Compare: GnRH antagonist depot Degarelix vs similar drugs
- Pricing: GnRH antagonist depot Degarelix cost, discount & access